Efficacy of Pentasa tablets for the treatment of inflammatory bowel disease

Journal of the Formosan Medical Association

Volumn 102, Issue 9, 2003, Pages 613-619

  Wong, Jau Min ^a   Wei, Shu Chen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Aminosalicyclic acids; Comparative study; Delayed action preparations; Inflammatory bowel diseases; Mesalamine

Indexed keywords

MESALAZINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DELAYED RELEASE FORMULATION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; ENDOSCOPY; ENTERITIS; FEMALE; HEMATOLOGIC DISEASE; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MAINTENANCE THERAPY; MALE; OPEN STUDY; PATIENT COMPLIANCE; RELAPSE; REMISSION; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MESALAMINE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0346496079     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Fallingborg J: Pentasa (Mesalazine) in Ulcerative Colitis and Crohn's Disease. Chester: Adis International;1992:9-13.
2. Wilding IR: A scintigraphic study to evaluate what happens to Pentasa® and Asacol® in the human gut. Practical Gastroenterol 1999;23:1-8.
3. Corrigan G, Stevens PE: Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 2000;14:1-6.
4. Kruis W, Bar-Meir S, Feher J, et al: The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroentrol Hepatol 2003;1:36-43.
5. Hanauer SB, Krawitt EL, Robinson M, et al: Long-term management of Crohn's disease with mesalamanie capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group. Am J Gastroenterol 1993;88:1343-51.
6. Fockens P, Mulder CJ, Tytgat GN, et al: Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. Eur J Gastroenterol Hepatol 1995;7:1025-30.
7. Porro GB, Ardizzone S, Petrillo M, et al: Pentasa dosage versus hydrocortisone in the topical treatment of active ulcerative colitis: a randomized, double-blind study. Am J Gastroenterol 1995;90:736-9.
8. Miner P, Hanauer S, Robinson M, et al: Safety and efficacy of controlled-release mesalamine for maintenace of remission in ulcerative colitis. Pentasa UC Maintenace Study Group. Dig Dis Sci 1995;40:296-304.
9. de-Vos M: Clinical pharmacokinetics of slow release mesalazine. Clin Pharmacokinet 2000;39:85-97.
10. Nugent SG, Kumar D, Ramton DS, et al: Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 2001;48:571-7.
11. Schroeder KW, Tremaine WJ, Ilstrup DM: Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-9.
12. Best WR, Becktel JM, Singleton JW: Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology 1979;77:843-6.
13. The Mesalamine Study Group: An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Ann Intern Med 1996;124:204-21.
14. Dew MJ, Hughes PJ, Lee MG: An oral preparation to release drugs in the human colon. Br J Clin Pharmacol 1982;4:405-8.
15. Fallingborg J, Pedersen P, Jacobsen BA: Small intestinal transit time and intraluminal pH in ileocecal resected patients with Crohn's disease. Dig Dis Sci 1998;43:702-5.